HK1249424A1 - 針對黑色素瘤優先表達抗原的t細胞受體及其用途 - Google Patents
針對黑色素瘤優先表達抗原的t細胞受體及其用途Info
- Publication number
- HK1249424A1 HK1249424A1 HK18109036.7A HK18109036A HK1249424A1 HK 1249424 A1 HK1249424 A1 HK 1249424A1 HK 18109036 A HK18109036 A HK 18109036A HK 1249424 A1 HK1249424 A1 HK 1249424A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- melanoma
- directed against
- cell receptors
- preferentially expressed
- expressed antigen
- Prior art date
Links
- 101001095088 Homo sapiens Melanoma antigen preferentially expressed in tumors Proteins 0.000 title 1
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464489—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562130884P | 2015-03-10 | 2015-03-10 | |
PCT/IB2016/000399 WO2016142783A2 (en) | 2015-03-10 | 2016-03-09 | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1249424A1 true HK1249424A1 (zh) | 2018-11-02 |
Family
ID=55948899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109036.7A HK1249424A1 (zh) | 2015-03-10 | 2018-07-11 | 針對黑色素瘤優先表達抗原的t細胞受體及其用途 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20160263155A1 (zh) |
EP (3) | EP3268014B1 (zh) |
JP (5) | JP2018510627A (zh) |
AU (1) | AU2016230828B2 (zh) |
CA (2) | CA2978171A1 (zh) |
ES (1) | ES2933030T3 (zh) |
HK (1) | HK1249424A1 (zh) |
WO (1) | WO2016142783A2 (zh) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3035075A1 (en) | 2016-09-23 | 2018-03-29 | Fred Hutchinson Cancer Research Center | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
EP3579877A4 (en) * | 2017-02-09 | 2020-12-09 | The Regents of The University of California | CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE |
US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
DE102017106305A1 (de) * | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
US20210147507A1 (en) | 2017-05-09 | 2021-05-20 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
CN108929378B (zh) * | 2017-05-22 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种识别prame抗原的t细胞受体及编码该受体的核酸 |
GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
CN117264963A (zh) * | 2017-12-13 | 2023-12-22 | 艾诺奥医药品有限公司 | 靶向prame的癌症疫苗和其用途 |
CN110272482B (zh) * | 2018-03-14 | 2022-08-19 | 中国科学院广州生物医药与健康研究院 | 识别prame抗原短肽的t细胞受体 |
EP3908292A4 (en) * | 2019-01-07 | 2023-01-04 | Children's National Medical Center | ENHANCED TARGETED T LYMPHOCYTE THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
EP4061827A1 (en) | 2019-11-18 | 2022-09-28 | BioNTech SE | Prame tcr receptors and uses thereof |
US20230060095A1 (en) * | 2020-01-24 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof |
CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
CN111693702A (zh) * | 2020-07-11 | 2020-09-22 | 成都益安博生物技术有限公司 | 一种黑色素瘤的外周血tcr标志物及其检测试剂盒和应用 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN112980787B (zh) * | 2021-03-02 | 2022-03-15 | 深圳豪石生物科技有限公司 | 一种特异性杀伤肿瘤细胞的免疫细胞制剂及其制备方法和应用 |
IL308257A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Antigen binding proteins that uniquely bind PRAME |
WO2022234116A1 (en) * | 2021-05-07 | 2022-11-10 | Medigene Immunotherapies Gmbh | Combination of prame specific t cell receptors and chimeric co-stimulatory receptors |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
WO2023081925A1 (en) * | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024101994A1 (en) | 2022-11-11 | 2024-05-16 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T cell receptors directed against cancer-associated antigens and uses thereof |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
FR2610631B1 (fr) | 1987-02-09 | 1989-11-24 | Pasteur Institut | Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme |
US5869608A (en) | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
US5426027A (en) | 1993-05-20 | 1995-06-20 | The Government Of The United States Of America As Represented By The Secretary | Nucleic acid probes and methods for detecting Candida DNA cells in blood |
US5648226A (en) | 1993-07-22 | 1997-07-15 | Ludwig Institute For Cancer Research | Isolated peptides derived from tumor rejection antigens, and their use |
JPH09502086A (ja) | 1993-08-06 | 1997-03-04 | サイテル コーポレイション | 完全mage1遺伝子のクローニング及び特性決定 |
US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US5955596A (en) | 1996-07-26 | 1999-09-21 | American Cyanamid Company | NucA protein of Haemophilus influenzae and the gene encoding that protein |
US5965242A (en) | 1997-02-19 | 1999-10-12 | Eastman Kodak Company | Glow-in-the-dark medium and method of making |
EP1717248A1 (en) | 1997-06-04 | 2006-11-02 | Oxford Biomedica (UK) Limited | Tumor targeted vector |
GB0526210D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Vectors |
GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
DK2307551T3 (en) | 2008-06-18 | 2017-03-20 | Oxford Biomedica (Uk) Ltd | CLEANING RETROVIRAL VECTORS |
EP3018146A1 (en) * | 2009-11-18 | 2016-05-11 | MannKind Corporation | Monoclonal antibodies and diagnostic uses thereof |
WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
EP3326467B1 (en) * | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
WO2014138704A1 (en) * | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
EP3569253A1 (en) * | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
CN114395530A (zh) * | 2014-02-04 | 2022-04-26 | 凯德药业公司 | 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物 |
CN117402829A (zh) * | 2015-12-14 | 2024-01-16 | 贝里坤制药股份有限公司 | 用于治疗性细胞活化或消除的双重控制 |
-
2016
- 2016-03-09 WO PCT/IB2016/000399 patent/WO2016142783A2/en active Application Filing
- 2016-03-09 AU AU2016230828A patent/AU2016230828B2/en active Active
- 2016-03-09 US US15/065,567 patent/US20160263155A1/en not_active Abandoned
- 2016-03-09 EP EP16721219.0A patent/EP3268014B1/en active Active
- 2016-03-09 CA CA2978171A patent/CA2978171A1/en active Pending
- 2016-03-09 ES ES16721219T patent/ES2933030T3/es active Active
- 2016-03-09 CA CA3214521A patent/CA3214521A1/en active Pending
- 2016-03-09 EP EP22190314.9A patent/EP4201955A1/en active Pending
- 2016-03-09 EP EP23150885.4A patent/EP4219544A1/en active Pending
- 2016-03-09 JP JP2017547146A patent/JP2018510627A/ja active Pending
-
2018
- 2018-07-11 HK HK18109036.7A patent/HK1249424A1/zh unknown
-
2019
- 2019-07-24 US US16/521,430 patent/US20200054678A1/en active Pending
-
2021
- 2021-03-17 JP JP2021043580A patent/JP2021090467A/ja active Pending
- 2021-03-17 JP JP2021043579A patent/JP2021090466A/ja active Pending
-
2023
- 2023-01-17 JP JP2023004987A patent/JP2023033463A/ja active Pending
- 2023-01-17 JP JP2023004986A patent/JP2023033462A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2978171A1 (en) | 2016-09-15 |
EP3268014B1 (en) | 2022-09-21 |
JP2018510627A (ja) | 2018-04-19 |
JP2023033463A (ja) | 2023-03-10 |
JP2021090467A (ja) | 2021-06-17 |
WO2016142783A2 (en) | 2016-09-15 |
ES2933030T3 (es) | 2023-01-31 |
CA3214521A1 (en) | 2016-09-15 |
JP2023033462A (ja) | 2023-03-10 |
WO2016142783A3 (en) | 2016-11-10 |
AU2016230828B2 (en) | 2020-10-22 |
EP4201955A1 (en) | 2023-06-28 |
US20160263155A1 (en) | 2016-09-15 |
JP2021090466A (ja) | 2021-06-17 |
EP3268014A2 (en) | 2018-01-17 |
EP4219544A1 (en) | 2023-08-02 |
US20200054678A1 (en) | 2020-02-20 |
AU2016230828A1 (en) | 2017-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1249424A1 (zh) | 針對黑色素瘤優先表達抗原的t細胞受體及其用途 | |
IL283965A (en) | Antibodies against cd73 and their uses | |
IL275619A (en) | Amplified chimeric antigen receptors and their uses | |
SG10201912199XA (en) | Anti-tim-3 antibodies and use thereof | |
IL262095A (en) | Anti-pacap antibodies and their use | |
EP3541840C0 (en) | ANTI-HLA-G ANTIBODIES AND THEIR USE | |
HK1259455A1 (zh) | 抗原受體及其用途 | |
ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
SG11202103609YA (en) | T-cell receptors and uses thereof | |
IL247315A0 (en) | Anti-acth antibodies and their uses | |
IL282201B (en) | Anti-tensin c antibodies and their uses | |
HK1258886A1 (zh) | T細胞受體及其用途 | |
IL266049A (en) | Antibodies against o1 and their uses | |
IL266082A (en) | Anti-chikv antibodies and their use | |
IL264417A (en) | Anti-o2 antibodies and their uses | |
IL269213A (en) | Antigen receptors and their uses | |
PL3347376T3 (pl) | Nowy receptor IGFR-podobny i jego zastosowania | |
GB201619818D0 (en) | Anti-idiotypic antibodies and uses thereof |